IPO Plus

₹48.53

▼ -0.53 -1.08%

As of 05 Aug 2026 · delayed

NSE Listed · Healthcare

ST-ASM · ASM 1
What does ST-ASM · ASM 1 mean?
BSE · Short Term Additional Surveillance Measure (ASM 1)ST-ASM catches short bursts: a beta-adjusted close-to-close move beyond ±25% in 5 trading days (or ±40% in 15) combined with concentrated trading — or a 75%+ monthly range with fewer than 100–200 unique traders. Practical meaning: margins jump to 50–100% for a few weeks to cool a spike; it either lapses quickly or escalates into LT-ASM if the move sustains.Criteria: Short-term (5 / 15 / 30-day) price-volume abnormality — high-low and close-to-close price variation over the window. Adds 100% margin and a 5% (then 2%) price band.Exchange notice · 2026-08-04
NSE · Short Term Additional Surveillance Measure (ASM 1)ST-ASM catches short bursts: a beta-adjusted close-to-close move beyond ±25% in 5 trading days (or ±40% in 15) combined with concentrated trading — or a 75%+ monthly range with fewer than 100–200 unique traders. Practical meaning: margins jump to 50–100% for a few weeks to cool a spike; it either lapses quickly or escalates into LT-ASM if the move sustains.Criteria: Short-term (5 / 15 / 30-day) price-volume abnormality — high-low and close-to-close price variation over the window. Adds 100% margin and a 5% (then 2%) price band.Exchange notice · 2026-08-04

Medico Remedies Limited (MEDICO)

Volume: 6,71,646Avg Vol 1W: 8,68,494Avg Vol 1M: 3,12,10252W Range:₹30.22₹56.88
NSE BSE medicoremedies.com AI Report
Key Ratios
Checked 9h ago
Market Cap₹403 Cr
Current Price₹48.53
Previous Close₹49.06
High / Low (52w)₹56.88 / ₹30.22
Volume6,71,646
Avg Vol (1W)8,68,494
Avg Vol (1M)3,12,102
Stock P/E68.35
Book Value₹9.09
Dividend Yield0%
ROE17.38%
ROA8.55%
Revenue (TTM)₹206 Cr
Revenue Growth—
Profit Margin6.36%
Total Debt—
Shares Outstanding8 Cr
Face Value₹2
EPS (TTM)₹0.71
P/B5.34
Debt / Equity—
50 DMA₹42.59
200 DMA₹45.44
Day change-1.08%
SurveillanceST-ASM · ASM 1
Price Chart
₹48.53▲ 24.88% · 1Y
₹55₹3348.4L
2025-08-06
2026-08-05

20-day avg volume: 3.4L shares

Pros
  • Healthy return on equity of 17.4%.
  • Net profit is growing year over year.
Cons
  • Stock trades at a high P/E of 68.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹31 Cr₹39 Cr₹39 Cr₹41 Cr₹38 Cr₹53 Cr₹59 Cr₹57 Cr
EBITDA₹2 Cr₹2 Cr₹4 Cr₹6 Cr₹3 Cr₹4 Cr₹4 Cr₹9 Cr
Net Profit₹2 Cr₹2 Cr₹3 Cr₹4 Cr₹2 Cr₹3 Cr₹3 Cr₹6 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue₹62 Cr₹100 Cr₹91 Cr₹123 Cr₹123 Cr₹144 Cr₹147 Cr₹154 Cr
EBITDA₹3 Cr₹3 Cr₹3 Cr₹5 Cr₹7 Cr₹11 Cr₹12 Cr₹15 Cr
Net Profit₹1 Cr₹2 Cr₹2 Cr₹3 Cr₹5 Cr₹7 Cr₹8 Cr₹10 Cr
EPS3.653.783.931.560.580.8711.22
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹76 Cr₹75 Cr₹76 Cr₹77 Cr₹87 Cr₹96 Cr₹120 Cr₹153 Cr
Total Liabilities₹48 Cr₹45 Cr₹43 Cr₹41 Cr₹44 Cr₹44 Cr₹57 Cr₹78 Cr
Equity₹28 Cr₹30 Cr₹32 Cr₹37 Cr₹44 Cr₹52 Cr₹62 Cr₹75 Cr
Total Debt———————₹19 Cr
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹-10 Cr₹8 Cr₹11 Cr₹6 Cr₹9 Cr₹6 Cr
Investing₹-17 Cr₹-2 Cr₹-7 Cr₹-3 Cr₹-3 Cr₹-5 Cr
Financing₹18 Cr₹-6 Cr₹-2 Cr₹0 Cr₹-1 Cr₹-55,00,000 Cr
Free Cash Flow₹-10 Cr₹8 Cr₹11 Cr₹6 Cr₹9 Cr₹1 Cr
Shareholding
Promoter 61.38% Institutions 0.08% Public 38.54%
About Medico Remedies Limited

Healthcare · Drug Manufacturers - Specialty & Generic

Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics; antimalarials; dry syrups; ointments and creams; anti-diabetics; syrups; and miscellaneous products, as well as diuretics, antireterovirals, and steroidal preparations. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India.

medicoremedies.com ↗
Efficiency & Working Capital
ROCE21%
Interest Coverage12.6
Dividend Payout—
Debtor Days138 d
Inventory Days65 d
Payable Days84 d
Cash Conversion Cycle119 d
Working Capital Days203 d
Shareholding Details

As of 2026-06-30

Promoter61.4%
FII0.1%
DII0%
Institutions0.1%
Public38.5%
Promoter Pledge0%
No. of Shareholders15,863
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters73.3%73.3%73.3%73.3%73.3%66.8%63.8%62.6%61.4%61.4%61.4%61.4%
FIIs1.1%1.3%0.3%0.2%0.2%0.4%0.1%0.1%0.3%0.5%0%0.1%
DIIs0%0%0.7%1%1%0.8%0%0%0%0%0%0%
Public25.5%25.4%25.6%25.5%25.5%32%36.1%37.3%38.3%38.1%38.6%38.5%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders5,2646,05210,68512,90212,88714,10415,42416,47418,50316,56216,18915,863
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503————
Major Shareholders (>1%)
NameCategoryStakeShares
Haresh Kapurlal MehtaShareholding of Promoter and Promoter Group20.2%1.68 Cr
Mehta Rishit HareshbhaiShareholding of Promoter and Promoter Group12.7%1.05 Cr
Harshit Haresh MehtaShareholding of Promoter and Promoter Group10.4%86,20,000
Rita H MehtaShareholding of Promoter and Promoter Group8.1%66,78,000
Ravi GoyalPublic Shareholding6.8%56,64,309
Shweta Harshit MehtaShareholding of Promoter and Promoter Group5.9%48,82,170
Priyal Rishit MehtaShareholding of Promoter and Promoter Group4.2%34,77,775
Haresh K Mehta HufShareholding of Promoter and Promoter Group0%0
Harshit H Mehta HufShareholding of Promoter and Promoter Group0%0
Board of Directors
NameDesignationYear
Haresh MehtaChairman & Executive Director & CFO2025
Harshit MehtaED / MD / Promoter2025
Rishit MehtaE D & Wholetime Director2025
Rita MehtaNon-Exec & Non-Independent Dir2025
Deepak VekariaIndependent Non Exe. Director2025
Bharat RathodIndependent Non Exe. Director2025
Deepesh Rajesh ShahIndependent Non Exe. Director2025
Kunal VoraIndependent Non Exe. Director2025
Anuj Kishore ModyIndependent Non Exe. Director2025
Maheshkumar DarjiIndependent Non Exe. Director2025
Vidhi Ankit ShahCompany Sec. & Compli. Officer2025
Segments — Product
SegmentRevenueShare
Manufacturers of Pharmaceutical For₹0 Cr—
Segments — Geography
RegionRevenueShare
India₹7 Cr13.6%
Outside India₹45 Cr86.4%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹2171717
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025000404
2025000202
2025000203
Insider / Designated-Person Trades

13 recent disclosure(s)

Shweta Harshit MehtaDisposal · 2,00,000
Harshit H Mehta HUFDisposal · 2,50,000
Harshit H Mehta HUFDisposal · 4,00,000
Rishit Haresh MehtaDisposal · 14,00,000
Rishit Haresh MehtaDisposal · 4,00,000
Shweta Harshit MehtaDisposal · 9,00,000
Substantial Acquisitions (SAST)

2 disclosure(s)

Market24/09/2025 - 25/09/2025 · 5,00,000
Market24/09/2025 - 25/09/2025 · 5,00,000
Company Information
Incorporated1994
ChairmanHaresh Mehta
AuditorV J Shah & Co/Shah Shroff & Associates
Investor Email[email protected]
🌐 www.medicoremedies.com ↗

📍 1105/1106 11-Flr Hubtown Solar, N S Phadke Marg Andheri East, Mumbai, Maharashtra, 400069

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Mcon Rasayan India Ltd.Multi Commodity Exchange of India Ltd.Marvel Decor LimitedGlobal Health LimitedMedi Assist Healthcare Services Ltd.Medicamen BiotechMedicamen Organics Ltd.Medistep Healthcare Ltd.Medplus Health Services Ltd.Meesho LimitedMega Flex Plastics Ltd.Megastar Foods LimitedAll “M” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search

Telegram App